Special Issue "Peptides of Natural Origins as Leads for Drug Discovery: From Native Structures to Peptidomimetics, Peptide-Conjugates, and Peptide-Nanoparticles"

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Drug Discovery and Development".

Deadline for manuscript submissions: 30 April 2021.

Special Issue Editors

Prof. Dr. Luca Gentilucci
Website
Guest Editor
1. Dept. of Chemistry "G. Ciamician", "Alma Mater Studiorum" - University of Bologna, Bologna, Italy
2. CIRI Health Sciences and Technologies (HST), Bologna,Italy
Interests: peptides; peptidomimetics; nitrogen heterocycles; conformational analysis; docking; opioids; integrins; addiction; cancer; biomaterials; diagnostic devices; inflammation
Dr. Fernando Albericio
Website
Guest Editor
1. School of Chemistry, University of KwaZulu-Natal, Durban
2. Department of Organic Chemistry, University of Barcelona, CIBER-BBN, Barcelona, Spain
Interests: antimicrobial peptides; solid-phase chemistry; combinatorial chemistry; drug delivery systems; peptide drug conjugates; orthogonal chemistry; drug discovery; biomaterials
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

Despite of recent scientific and technological advances, drug R&D productivity continues its exponential decline, dramatically depicted by the “Eroom’s Law”. This negative trend has encouraged pharmaceutical companies to reconsider bioactive natural peptides as valuable leads for drug discovery. After an initial enthusiasm until the 80s (human insulin was introduced in 1982 as the first recombinant drug), peptides almost sank into oblivion by the end of the 20th century. The reasons for this largely stem from the prejudice that the cons greatly outweigh the pros. Native peptides may suffer from poor metabolic stability, scarce to null ability to penetrate across biological barriers, and rapid clearance. Besides, inefficient and expensive manufacturing hampered the production of large amounts of peptides. Nevertheless, the past two decades have seen a significant increase in the investments in peptide drug discovery. The case of enfuvirtide demonstrated that producing a 36-residue peptide on a ton-scale per year could be cost effective. Additionally, the recourse to alternative routes of administration (e.g., pulmonary, nasal, intradermal), to the peptidomimetic strategy, and the conjugation to carriers or nanoparticles, allowed the bioavailability of native structures to be improved. Therapeutic peptides offer several advantages over small molecules—that is, greater efficacy and specificity, reduced toxicity, and reduced accumulation. Compared with proteins and antibodies, peptides have lower manufacturing costs and higher activity per unit mass, are less immunogenic, can be stored for longer periods, and have the potential to penetrate into tissues owing to their smaller size. Finally, peptides require a shorter time to reach the market, and are less problematic in terms of royalty stack because of a simpler intellectual property.

The global peptide therapeutics market was valued at USD 21.5 billion in 2016, and is expected to grow at a rate of 9.4% per year, reaching USD 48.04 billion by 2025. Presently, more than 60 peptide therapeutics are marketed worldwide, another ca. 170 are in various stages of clinical development, and more than 200 others are at preclinical stages. The predominant therapeutic areas are in metabolic diseases and oncology, followed by infections, cardiovascular, respiratory, renal, and gastro-intestinal disorders, pain, CNS, and dermatology. The year 2017 was exceptional for peptide and peptidomimetic drugs, with six approved in comparison with one in 2016: angiotensin II (control of blood pressure), etelcalcetide (secondary hyperparathyroidism), plecanatide (chronic idiopathic constipation), abaloparatide (osteoporosis), semaglutide (type 2 diabetes mellitus), and macimorelin (GH deficiency).

In this Issue, we intend to present the recent trends in peptide drug discovery, from the naturally occurring peptides to the peptidomimetics, from therapeutic applications to the new opportunities enabled by the conjugation with biomaterials and nanotechnology.

Prof. Dr. Luca Gentilucci
Prof. Dr. Fernando Albericio
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • peptide
  • peptidomimetic
  • conjugate
  • glycopeptide
  • drug discovery
  • delivery
  • cancer
  • opioid
  • metabolic
  • cardiovascular
  • antibiotic
  • synthesis
  • ligation
  • recombinant
  • GCPR
  • library
  • phage display
  • mRNA display
  • nonribosomal
  • nonstandard
  • toxin
  • lantibiotic
  • cyclotide
  • bicyclic
  • cell-penetrating

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle
Physicochemical and Biological Examination of Two Glatiramer Acetate Products
Biomedicines 2019, 7(3), 49; https://doi.org/10.3390/biomedicines7030049 - 03 Jul 2019
Cited by 1
Abstract
Herein we compared 40 mg/mL lots of the active ingredient, glatiramer acetate, manufactured by Mylan/Natco to the active ingredient, glatiramer acetate in Copaxone (Teva Pharmaceuticals, Ltd., Netanya Israel) using physicochemical (PCC) methods and biological assays. No differences were seen between the Mylan/Natco and [...] Read more.
Herein we compared 40 mg/mL lots of the active ingredient, glatiramer acetate, manufactured by Mylan/Natco to the active ingredient, glatiramer acetate in Copaxone (Teva Pharmaceuticals, Ltd., Netanya Israel) using physicochemical (PCC) methods and biological assays. No differences were seen between the Mylan/Natco and Teva lots with some low resolution release PCC assays (amino acid analysis, molecular weight distribution, interaction with Coomassie Brilliant Blue G-250). Changes in polydispersity between Mylan/Natco and Copaxone lots were found using size exclusion chromatography and the high resolution PCC method, known as Viscotek, and suggestive of a disparity in the homogeneity of mixture, with a shift towards high molecular weight polypeptides. Using RPLC-2D MALLS, 5 out of 8 Mylan/Natco lots fell outside the Copaxone range, containing a high molecular weight and high hydrophobicity subpopulation of polypeptides not found in Copaxone lots. Cation exchange chromatography showed differences in the surface charge distribution between the Copaxone and Mylan/Natco lots. The Mylan/Natco lots were found to be within Copaxone specifications for the EAE model, monoclonal and polyclonal binding assays and the in vitro cytotoxicity assay, however higher IL-2 secretion was shown for three Mylan/Natco lots in a potency assay. These observations provide data to inform the ongoing scientific discussion about the comparability of glatiramer acetate in Copaxone and follow-on products. Full article
Show Figures

Figure 1

Review

Jump to: Research

Open AccessReview
Integrin-Targeting Peptides for the Design of Functional Cell-Responsive Biomaterials
Biomedicines 2020, 8(9), 307; https://doi.org/10.3390/biomedicines8090307 - 25 Aug 2020
Cited by 2
Abstract
Integrins are a family of cell surface receptors crucial to fundamental cellular functions such as adhesion, signaling, and viability, deeply involved in a variety of diseases, including the initiation and progression of cancer, of coronary, inflammatory, or autoimmune diseases. The natural ligands of [...] Read more.
Integrins are a family of cell surface receptors crucial to fundamental cellular functions such as adhesion, signaling, and viability, deeply involved in a variety of diseases, including the initiation and progression of cancer, of coronary, inflammatory, or autoimmune diseases. The natural ligands of integrins are glycoproteins expressed on the cell surface or proteins of the extracellular matrix. For this reason, short peptides or peptidomimetic sequences that reproduce the integrin-binding motives have attracted much attention as potential drugs. When challenged in clinical trials, these peptides/peptidomimetics let to contrasting and disappointing results. In the search for alternative utilizations, the integrin peptide ligands have been conjugated onto nanoparticles, materials, or drugs and drug carrier systems, for specific recognition or delivery of drugs to cells overexpressing the targeted integrins. Recent research in peptidic integrin ligands is exploring new opportunities, in particular for the design of nanostructured, micro-fabricated, cell-responsive, stimuli-responsive, smart materials. Full article
Show Figures

Figure 1

Open AccessReview
Protein Nanotubes: From Bionanotech towards Medical Applications
Biomedicines 2019, 7(2), 46; https://doi.org/10.3390/biomedicines7020046 - 23 Jun 2019
Cited by 5
Abstract
Nanobiotechnology involves the study of structures found in nature to construct nanodevices for biological and medical applications with the ultimate goal of commercialization. Within a cell most biochemical processes are driven by proteins and associated macromolecular complexes. Evolution has optimized these protein-based nanosystems [...] Read more.
Nanobiotechnology involves the study of structures found in nature to construct nanodevices for biological and medical applications with the ultimate goal of commercialization. Within a cell most biochemical processes are driven by proteins and associated macromolecular complexes. Evolution has optimized these protein-based nanosystems within living organisms over millions of years. Among these are flagellin and pilin-based systems from bacteria, viral-based capsids, and eukaryotic microtubules and amyloids. While carbon nanotubes (CNTs), and protein/peptide-CNT composites, remain one of the most researched nanosystems due to their electrical and mechanical properties, there are many concerns regarding CNT toxicity and biodegradability. Therefore, proteins have emerged as useful biotemplates for nanomaterials due to their assembly under physiologically relevant conditions and ease of manipulation via protein engineering. This review aims to highlight some of the current research employing protein nanotubes (PNTs) for the development of molecular imaging biosensors, conducting wires for microelectronics, fuel cells, and drug delivery systems. The translational potential of PNTs is highlighted. Full article
Show Figures

Figure 1

Back to TopTop